Elanco Animal Health Inc ELAN
Elanco Animal Health Inc (NYSE: ELAN) is an animal health company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Zenrelia | Pruritus and atopic dermatitis in dogs (JAK inhibitor) | small molecule | NA_NON_THERAPEUTIC |
| Credelio Quattro | Fleas, ticks, heartworm and intestinal worms in dogs | small molecule | NA_NON_THERAPEUTIC |
| Befrena | Canine allergic and atopic dermatitis (anti-IL31 monoclonal antibody) | antibody | NA_NON_THERAPEUTIC |
| Bovaer (3-NOP) | Methane-reducing feed ingredient for lactating dairy cattle | small molecule | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.